#ASCO21: J&J busts out a small update for its antibody-TKI combo in lung cancer — whetting appetites as FDA thinks it over
In a red-hot EGFR-mutated non-small cell lung cancer market, Johnson & Johnson thinks it could have a leader in its bispecific antibody amivantamab. But as competitors crowd in, J&J is looking to back up its case for approval, and it’s rolling out just a taste of that data to back its case in rare mutations.
A combination of J&J’s EGFR/MET bispecific antibody amivantamab and small-molecule TKI drug lazertinib posted a median duration of response of 9.6 months in patients with NSCLC with exon 19 deletion or L858R mutation that hadn’t previously undergone chemo but previously failed on AstraZeneca’s Tagrisso, according to cohort data from the Phase I/II CHRYSALIS study set to be presented at ASCO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.